- Why Cancer Cells in Prostate Cancer Develop Resistance to Hormone Therapy: Mechanisms of second-generation androgen receptor antagonist resistance in neuroendocrine prostate cancer
Maximilian Marhold, University Department of Internal Medicine I - Search for Biomarkers for Liquid Biopsy in Recurrent Brain Tumors in Children: Identification of new CSF biomarkers and evaluation in recurrent MB or ATRT patients
Sibylle Madlener, University Clinic for Pediatrics and Adolescent Medicine - The Question of the Causes of Thrombosis in Brain Tumors: The role of podoplanin and neutrophil extracellular traps (NETs) in the development of cancer-associated thrombosis
Cihan Ay, University Department of Internal Medicine I - Investigating Treatment Resistance in Metastatic Colorectal Cancer: Use of Organoid Technology to Predict Therapy Response and Develop Novel Strategies to Enhance Efficacy of anti-EGFR Therapy in Colorectal Cancer Patients
Angelika Neuhofer, Institute for cancer research - On the idea of boosting the immune system through radiation therapy to fight colorectal cancer: Tumor-associated macrophages in the context of the leukocytic infiltration in irradiated human rectal cancer and 3D co-culture models
Victoria Stary, University Department of Surgery - An Attempt to Reprogram the Communication of Lung Cancer Cells: A20: A master regulator of the tumor microenvironment
Herwig Moll, Center for Physiology and Pharmacology - A new approach to understanding the development of myelodysplastic syndrome and developing innovative treatment strategies: Disruption of the C/EBP-PU.1 axis results in myelodysplasia: characterization of a novel diesease-driving pathway linking hematopoietic progenitor cells and the bone marrow microenvironment
Lukas Kazianka, University Department of Internal Medicine I - The Search for the Origin of Chronic Lymphocytic Leukemia: Characterization of NOTCH2 gain of function N2ΔEC deletions as possible causal genetic lesion in CLL
Rainer Hubmann, University Department of Internal Medicine I - In search of the mechanism by which pancreatic cancer cells prepare for metastasis: Semaphorin 3A in pancreatic cancer metastasis: role as driver, biomarker, and novel therapeutic target
Robert Eferl, Institute for cancer research - New Biomarkers for Treatment Response in Metastatic Melanoma: Identification of novel markers to predict response to anti-PD-1 immunotherapy in melanoma applying proteomics
Verena Paulitschke, University Department of Dermatology
- Characterization of Tumor Markers for Cancer Treatment in Ductal Adenocarcinoma of the Pancreas
Daniela Bianconi, University Clinic for Internal Medicine I - The Role of MicroRNA 21 in Pleural Cancer
Michael Grusch, Institute for Cancer Research - A translational research approach for improved molecular characterization of leiomyosarcomas
Rainer Hamacher, Department of Internal Medicine I Molecular mechanisms contributing to the synergy between systemic cancer therapies and immune checkpoint inhibitors
Christine Pirker, Institute for Cancer Research
Tumor Immunology of Brain Metastases
Anna Berghoff, Department of Internal Medicine IOcular Blood Flow in Patients with Colorectal Tumors Before and After Anti-Angiogenic Therapy
Thorsten Füreder, Department of Internal Medicine ITumor-Specific Activation of Clinically Approved Tyrosine Kinase Inhibitors by Cathepsin B
Petra Heffeter, Institute for Cancer ResearchFunctional Characterization of Epigenetically Silenced Genes L1TD1 and ZNF677 in Non-Small Cell Lung Cancers
Gerwin Heller, University Clinic for Internal Medicine IMolecular mechanisms of resistance development to anti-EGFR therapy in head and neck squamous cell carcinoma
Martin Holcmann, Institute for Cancer ResearchNew aspects in the administration of IMiDs in mucosa-associated lymphoid tissue
Barbara Kiesewetter, University Clinic for Internal Medicine IAntitumor Activity of KP46 in Relation to p53
Karin Nowikovsky, University Clinic for Internal Medicine IEXACT: Extended Analysis for Cancer Treatment
Gerald Prager, University Clinic for Internal Medicine I
“Targeted Attack on the Tumor Cell”—article on the EXACT study in “Die Presse” from October 3, 2013, available for downloadEstablishment of a Multicenter Registry for Critically Ill Cancer Patients in Intensive Care Units
Peter Schellongowski, University Clinic for Internal Medicine IPreclinical Evaluation and Functional Analysis of Gliotoxin, an Effective Inhibitor of the NOTCH Receptor in Chronic Lymphocytic Leukemia
Medhat Shehata, Comprehensive Cancer Center
- Genomic signatures of malignant pleural mesothelioma: impact on progression and therapy response
Univ. Lektor Ao. Univ. Prof. Mag. Dr. Walter Berger - Targeting urokinase plasminogen activator receptor (uPAR)/integrin complex formation, a signaling orchestrator in cancer
Priv. Doz. Dr. Gerald W. Prager - Selective targeting of the tumor cells and protection of the mesenchymal stem cells
Dr. Medhat Shehata - Do BCL6 mutations reduce susceptibility of CLL cells to induction of apoptosis during therapy?
Ao. Univ. Prof.in Dr.in Jozefa Gadek-Wesierski - Genome-wide screening for genetic variations associated with aggressive prostate cancer risk
Ao. Univ. Prof.in Mag.a Dr.in Andrea Gsur - Mechanism of action of the combination FOLFIRI + cetuximab in the KRAS mutant colon carcinaoma in vitro
Ao. Univ. Prof. DI Dr. Robert Mader, Ao. Univ. Prof. Dr. Thomas Brodowicz, Ao. Univ. Prof.in Dr.in Jozefa Gadek-Wesierski - Targeting of neoplastic stem cells in solid tumors and other neoplasms
Ao. Univ. Prof. Dr. Peter Valent, Ao. Univ. Prof. Mag. Dr. Thomas Grunt - Humanisation in Intensive Care Medicine
Ao. Univ. Prof. Dr. Klaus Laczika
Glioblastoma is an increasingly common, extremely aggressive brain tumor that is very difficult to treat. Consequently, in most cases, this tumor leads to the patient’s death very rapidly. The goal of the project is to decipher the molecular basis of this tumor’s resistance to treatment and its aggressiveness using state-of-the-art molecular genetic technologies and, based on the data obtained, to develop new therapeutic strategies.
Kira Brämswig and Gerald Prager are investigating angiogenesis—the formation of new blood vessels—a process that plays a key role in the development of cancer. Anti-angiogenic therapies used clinically to date have achieved only partial and, at times, temporary success in cancer treatment. A better understanding of the functional mechanism by which certain tumor markers influence the pro-angiogenic behavior of endothelial cells is a fundamental prerequisite for identifying new therapeutic targets in anti-angiogenic cancer therapy.
Cetuximab (Erbitux®) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It has recently been demonstrated that cetuximab, in combination with chemotherapy, significantly prolongs survival in patients with NSCLC. Cetuximab will therefore have a major impact on the treatment of NSCLC in the future. Due to pre-existing resistance or resistance acquired during the course of therapy, not all patients benefit from this treatment. The project aims to help characterize the clinically relevant resistance mechanisms to cetuximab therapy in patients with NSCLC and to enable the selection of patients for this treatment option in the future.
Melanoma is the most aggressive form of skin cancer, and its incidence has risen sharply in recent years. It metastasizes early and is then difficult to treat with currently available medications. In the project led by Michael Grusch and colleagues, researchers are investigating the effects of a new class of substances that specifically block the receptor for fibroblast growth factor (FGF), which is essential for melanoma cells.
Multiple myeloma (MM) is a cancer of the bone marrow characterized by a highly variable clinical course. To better understand this, this project aims to investigate the characteristics of myeloma cells with regard to their production of a wide variety of proteins and signaling molecules. Through this, the researchers expect to gain insights not only into the disease itself but also into which patterns correspond to specific therapies (chemotherapy, targeted therapies).
Katrina Vanura is studying the enzyme UGT2B17, which is a new prognostic factor in chronic lymphocytic leukemia. Patients with high expression of the corresponding gene appear to respond much less effectively to standard treatments. Katrina Vanura and her team are using a larger group of patients to investigate the role this enzyme plays in chronic lymphocytic leukemia and multiple myeloma.
- Detection of Methylated Tumor DNA in Serum as a Marker for Cancer
Alexandra Cee and Team
Download Poster - Optimizing Treatment for Tumors and Leukemias Using Heat Shock Protein 32
Karoline V. Gleixner and Team
Download Poster - Genetic Polymorphisms in DNA Repair Genes and the Risk of Colorectal Cancer
Andrea Gsur and Team
Download Poster - The Role of Deletions on Chromosome 20q in Myeloproliferative Disorders
Roland Jäger, Tiina Berg, Robert Kralovics
Download Poster - Identification and Modulation of MicroRNAs as Mediators of Chemoresistance
Robert Mader, Johannes Grillari, Walter Berger
Download Poster - CD98, a New Therapeutic Target in Oncology
Gerald Prager and Team
Download Poster
- Molecular Mechanisms Underlying the Activity of ErBB Inhibitors in Cancer Cells
- Michael Grusch and Team
- Association Between Hypoxia and Telomerase Activity in WHO Grade II–IV Astrocytic Tumors
- Klaus Holzmann and Team
- Functional Analysis of N33 (TUSC3), a Gene of High Prognostic Significance in Ovarian Cancer
- Michael Krainer and Team
- Stem Cells in Colorectal Cancer and Its Precursor—Colorectal Polyps
- Brigitte Marian and Team
- Inhibition of the PI3-kinase signaling pathway, taking into account the lymphoid “microenvironment,” as an innovative treatment strategy for B-cell chronic lymphocytic leukemia
- Medhat Shehata and Team
- Hemoxygenase 1 (HO-1) as a Therapeutic Target in Solid Tumors and Leukemias
- Peter Valent and Team
- Development of a Three-Dimensional Tumor Model
- Ansgar Weltermann and Team
- Identification of Genes Regulated by Epigenetic Mechanisms in Bronchial Carcinomas
- Sabine Zöchbauer-Müller and Team
- Download Poster